FEB 03, 2020 3:02 PM PST

HIV Viral Structures Improve Therapeutics

WRITTEN BY: Nouran Amin

Researchers have recently discovered how a powerful class of HIV drugs bind to a key piece of HIV machinery. Their findings, for the first time, shows how HIV therapy can be potent.

"The drugs we studied are the latest compounds available in the clinic today, as well as several important pre-clinical molecules. Until now, no one knew exactly how they bound to this HIV complex," says the study's senior author Dmitry Lyumkis, an assistant professor in Salk's Laboratory of Genetics. "A better understanding of how the drugs work will help us improve them and design new therapeutic compounds."

The intasome is a critical part of the HIV structure of which enables infection by integrating the virus’s genetic material into human DNA. This is why some drugs, called integrase strand transfer inhibitors (INSTIs), treat HIV by blocking the actions of intasome.

Even through these drugs were a success—scientists still struggled to examine how they inhibited the HIV intasome.

"To this day, everyone is still using the PFV intasome structure to rationalize and understand the mechanism of action of these drugs," says Dario Passos, the study's co-first author and a staff scientist in Lyumkis' laboratory. "But we've shown that the field really needs to move and study the HIV structure if we want to make further progress."

"We and many others have been working towards this goal for several decades and it is exciting that at long last we can now understand how HIV inhibitors work in detail and aid the development of new drugs." says Min Li, co-first author and a staff scientist at the National Institute of Diabetes and Digestive and Kidney Diseases.

In the study, researchers obtained the structure of HIV intasomes while they were being actively blocked by one of four INSTIs. They observed that a compound known as 4f has unique qualities in binding to HIV and thus can help improve the binding properties of potential future molecules.

"In previous structures, we learned about intasome biology," says Lyumkis. "But here, we've really started to gain insight into the therapeutic angle of how drugs can target these important viral assemblies."

Source: Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 26, 2020
Immunology
Armed With ImmunoBait, Red Blood Cells Fight Lung Cancers
NOV 26, 2020
Armed With ImmunoBait, Red Blood Cells Fight Lung Cancers
  There’s a new weapon in the battle against lung cancer metastases: red blood cells equipped with nanopartic ...
NOV 26, 2020
Cannabis Sciences
Women More Likely than Men to Swap Prescription Medication for Cannabis
NOV 26, 2020
Women More Likely than Men to Swap Prescription Medication for Cannabis
The stigma around cannabis usage is fading as cannabis laws become increasingly lax. Now, researchers from DePaul Univer ...
NOV 23, 2020
Drug Discovery & Development
Therapeutically Active Ion-Channels
NOV 23, 2020
Therapeutically Active Ion-Channels
Therapeutically relevant ion channels have inspired researchers to look into drugs that can regulate their activity. Ion ...
DEC 21, 2020
Drug Discovery & Development
Drug Increases Vaccine Responses
DEC 21, 2020
Drug Increases Vaccine Responses
A drug was found to increase the effects of vaccine responses in older adults. The drug works by removing cellular debri ...
DEC 28, 2020
Immunology
Inhaling a Puff of Llama Antibodies to Relieve COVID
DEC 28, 2020
Inhaling a Puff of Llama Antibodies to Relieve COVID
Scientists at the National Institutes of Health have identified new antibody-based weapons in the fight against COVID-19 ...
JAN 27, 2021
Drug Discovery & Development
Do Vaccines Work Against New Covid Variants?
JAN 27, 2021
Do Vaccines Work Against New Covid Variants?
The SARS-CoV-2 virus is mutating faster than scientists previously thought. As such, pharmaceutical companies are now sc ...
Loading Comments...